The quality control unit lacks responsibility to approve and reject all procedures or specifications impacting on the identity, strength, quality and purity of drug products.
Inspection Record
Promise Pharmacy, LLC — FDA 483 Findings
Inspectors Jennifer L HuntingtonThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
Your firm released drug produt in which the strength differs from, or its purity or quality falls below, that which it purports or is represented to possess.
The flow of components, drug product containers, closures and in-process materials though the building is not designed to prevent contamination.
There is no written testing program designed to assess the stability characteristics of drug products.
Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing.
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not.
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.
Equipment and utensils are not maintained at appropriate intervals to prevent malfunctions that would alter the safety, identity, strength, quality or purity of the drug product.
About this record
Extracted automatically from the document US FDA published on 2019-04-30. The source is available at the link above.
This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.
Translation and classification are automated and may differ in nuance from the source.
